Results 51 to 60 of about 6,879 (203)
Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection
1 Recently, a potential neuroprotective effect of rimonabant, independent of the CB1 receptor interaction, has been proposed. In the present study, the role of transient receptor potential channel vanilloid subfamily member 1, named VR1, on ...
A. Zani +4 more
core +1 more source
Effect of rimonabant on carotid intimaemedia thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: The AUDITOR Trial [PDF]
Objective: The aim of this trial was to determine whether obese patients benefit from treatment with rimonabant in terms of progression of carotid atherosclerosis.
Després, J.P. +34 more
core +1 more source
Anti-obesity activity of Erythrina subumbrans (Hassk.) Merr leaves extract in high fructose-induced obesity in Wistar rats [PDF]
Introduction: Obesity is known to lead to the development of metabolic disorders and Erythrina subumbrans (Hassk.) Merr has shown the potential in alleviating some diseases. This study aimed to assess the anti-obesity activity of the ethanol extract of E.
Elis Susilawati +5 more
doaj +1 more source
Rimonabant, Gastrointestinal Motility and Obesity [PDF]
Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects ...
Sun, Yan, Chen, Jiande
openaire +2 more sources
Cannabinoid‐Inspired Fluorescent Boroisoquinolines for CB1 Receptor Imaging
A cannabinoid‐inspired fluorescent boroisoquinoline, a low‐micromolar partial agonist of the human CB1 receptor, enabled imaging of CB1 receptors by confocal microscopy in live cells. The intrinsic fluorescence of our probe provides a unique opportunity for CB1 imaging while keeping receptor structure and pharmacology similar to that observed with ...
Dénes Szepesi Kovács +9 more
wiley +1 more source
Rimonabant—Ein Cannabinoid-Rezeptor-Antagonist zur Gewichtsreduktion und Rauchentwöhnung
Treatment of lifestyle risk factors such as and smoking is difficult. These risk factors play important roles in cardiovascular disease. Current therapeutic strategies only have minor impact on associated metabolic changes such as low HDL cholesterol and
Roberto Corti +3 more
core +1 more source
After discontinuation of semaglutide or tirzepatide, weight regain averaged 1.04 kg/month. Based on a linear model, half of treatment‐associated weight loss was projected to return by approximately 7.5 months and baseline weight by approximately 15 months, highlighting the need for early monitoring and maintenance planning.
Chia Siang Kow +3 more
wiley +1 more source
The endocannabinoid system represents an integrated neuronal network involved in the control of several organisms’ functions, such as feeding behavior. A series of hybrids of 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-
Marilisa P. Dimmito +7 more
doaj +1 more source
Obesity rates are increasing worldwide and there is a need for novel therapeutic treatment options. The endocannabinoid system has been linked to homeostatic processes, including metabolism, food intake, and the regulation of body weight.
Thomas Murphy, Bernard Le Foll
doaj +1 more source
The psychiatric side-effects of rimonabant [PDF]
OBJECTIVE: Experimental evidence has suggested that drugs that enhance cannabinoid type-1 (CB1) receptor activity may induce anxiolytic and antidepressant effects, whilst the opposite has been reported with antagonists. Thus, the objective of the present review is to discuss the potential psychiatric side-effects of CB1 receptor antagonists, such as ...
Fabrício A, Moreira +1 more
openaire +2 more sources

